嗜酸性粒细胞是目前严重难治性伴鼻息肉慢性鼻窦炎生物治疗指征中的主要2型标志物。

Eosinophils are the dominant type2 marker for the current indication of biological treatment in severe uncontrolled chronic rhinosinusitis with nasal polyps.

作者信息

van der Lans R, Otten J J, Adriaensen G F J P M, Benoist L B L, Cornet M E, Hoven D R, Rinia A B, Fokkens W J, Reitsma S

机构信息

Amsterdam Rhinology Team (ART), department of otorhinolaryngology and head/neck surgery, Amsterdam University Medical Centers, location AMC, Amsterdam, The Netherlands.

Department of otorhinolaryngology, Alrijne Hospital, Leiden, The Netherlands.

出版信息

Rhinology. 2024 Jun 1;62(3):383-384. doi: 10.4193/Rhin23.081.

DOI:10.4193/Rhin23.081

PMID:38478151

Abstract

The latest European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS2020) defines markers for type2 inflammation in the context of indicating biological therapy in severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) as either a total serum immunoglobulin E (total-IgE) <100 kU/L, a blood eosinophil count (BEC, expressed as -109 cells / L) >=0.25, or a tissue eosinophil count >=10 per high power field (HPF) (1). Recently, an EPOS/EUFOREA expert panel advised to lower the threshold for BEC from >=0.25 (EPOS2020) to >=0.15 (EUFOREA2023) to align with thresholds used for biological indication in asthma patients (2). As far as we know, there is no literature supporting the cut-off value for total-IgE.

摘要

最新的《欧洲鼻窦炎和鼻息肉立场文件（2020版）》定义了在重度未控制的慢性鼻窦炎伴鼻息肉（CRSwNP）中进行生物治疗时2型炎症的标志物，即血清总免疫球蛋白E（总IgE）<100 kU/L、血液嗜酸性粒细胞计数（BEC，以-109细胞/L表示）>=0.25或组织嗜酸性粒细胞计数>=10/高倍视野（HPF）（1）。最近，一个EPOS/EUFOREA专家小组建议将BEC的阈值从>=0.25（EPOS2020）降至>=0.15（EUFOREA2023），以与哮喘患者生物治疗指征所使用的阈值保持一致（2）。据我们所知，尚无文献支持总IgE的临界值。